The test works by looking for cell-free nucleosomes in the blood. The study included 229 patients diagnosed with cancer and ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in ...

A new urine-based biomarker test could cut in half the need for surveillance imaging to detect recurrence of the most common ...

VolitionRx (VNRX) announces the results of a study which shows that an automated Nu.Q Cancer immunoassay test in development detected a range ...

Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We ...

The Mayo Clinic and Xact Sciences are developing an easy, noninvasive test to detect endometrial cancer in women with ...

In addition, the increasing focus on point-of-care testing (POCT) is propelling demand for portable and easy-to-use immunoassay analysers, specifically in resource-constrained settings.

Quick, on-the-spot drug tests, often called point-of-use or rapid tests, are designed to give a fast indication of possible ...

Palamina Corp. announces assay results from field work completed in February of 2025 in the Sol de Oro North zone at its 100% owned Usicayos gold project in Peru. Limited mapping and sampling programs ...

This screening process involves numerous assays ... damage to the system, or adversely affect assay results.